Literature DB >> 19144680

Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis.

Terry Gernsheimer1.   

Abstract

The mechanism of idiopathic (autoimmune) thrombocytopenic purpura (ITP) has historically been attributed to platelet autoantibody production and the resultant platelet destruction. More recent evidence suggests a multifactorial pathogenesis. A complex picture of the immune processes involved in autoimmunity has emerged over the last decade with the identification and characterization of immunoregulatory elements (receptors, cytokines, and other signaling molecules) and cell trafficking patterns. An understanding of the interplay of cellular and humoral immune responses in the breakdown of self-tolerance has brought to light unrecognized mechanisms of the autoimmune destruction of platelets in ITP and potential targets for future therapeutic advances. The failure of the bone marrow to maximally increase platelet production also appears to play an important role in the thrombocytopenia of ITP. Treatment strategies targeting the thrombopoietin receptor to increase platelet production are a promising new approach to the management of ITP.

Entities:  

Mesh:

Year:  2009        PMID: 19144680     DOI: 10.1634/theoncologist.2008-0132

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  28 in total

Review 1.  Advances in immunopathogenesis of adult immune thrombocytopenia.

Authors:  Xinguang Liu; Yu Hou; Jun Peng
Journal:  Front Med       Date:  2013-11-21       Impact factor: 4.592

2.  Initial Lymphocyte Count as Prognostic Indicator for Childhood Immune Thrombocytopenia.

Authors:  Sinan Akbayram; Kamuran Karaman; Murat Dogan; Lokman Ustyol; Mesut Garipardic; Ahmet Faik Oner
Journal:  Indian J Hematol Blood Transfus       Date:  2016-03-08       Impact factor: 0.900

Review 3.  Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.

Authors:  Bing-Bing Yang; Sameer Doshi; Karen Arkam; Janet Franklin; Andrew T Chow
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

4.  Privigen immune globulin intravenous (human), 10% liquid.

Authors: 
Journal:  P T       Date:  2011-08

5.  Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years.

Authors:  Nicola Vianelli; Francesca Palandri; Nicola Polverelli; Roberto Stasi; Joel Joelsson; Eva Johansson; Marco Ruggeri; Francesco Zaja; Silvia Cantoni; Angelo Emanuele Catucci; Anna Candoni; Enrica Morra; Magnus Björkholm; Michele Baccarani; Francesco Rodeghiero
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

6.  Complicated lower extremity wound caused by immune thrombocytopenic purpura leading to hypercoagulable state: a team approach for limb salvage.

Authors:  Richard Simman; John Haluschak; Sarah Jackson
Journal:  J Am Col Certif Wound Spec       Date:  2010-09-09

7.  In vitro TNF blockade enhances ex vivo expansion of regulatory T cells in patients with immune thrombocytopenia.

Authors:  Hui Zhong; James Bussel; Karina Yazdanbakhsh
Journal:  Br J Haematol       Date:  2014-09-24       Impact factor: 6.998

8.  Decreased IDO activity and increased TTS expression break immune tolerance in patients with immune thrombocytopenia.

Authors:  Chun-Yan Wang; Yan Shi; Ya-Nan Min; Xiao-Juan Zhu; Cheng-Shan Guo; Jun Peng; Xiao-Yuan Dong; Ping Qin; Jian-Zhi Sun; Ming Hou
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

9.  Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.

Authors:  Weili Bao; James B Bussel; Susanne Heck; Wu He; Marissa Karpoff; Nayla Boulad; Karina Yazdanbakhsh
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

10.  CD16+ monocytes control T-cell subset development in immune thrombocytopenia.

Authors:  Hui Zhong; Weili Bao; Xiaojuan Li; Allison Miller; Caroline Seery; Naznin Haq; James Bussel; Karina Yazdanbakhsh
Journal:  Blood       Date:  2012-08-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.